Authors: Kelly A. Deabold,Wayne S. Schwark,Lisa Wolf and Joseph J. Wakshlag Published in Animals 19 October 2019 Abstract The use of CBD-rich hemp products is becoming popular among pet…
Free Radical Biology and Medicine, October 2019
—
Perinatal asphyxia-induced brain injury may present as hypoxic-ischemic encephalopathy in the neonatal period, and disability including cerebral palsy in the long term. The brain injury is secondary to both the hypoxic-ischemic event and the reoxygenation-reperfusion following…
Anticancer Research, October 2019
—
Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent y…
Complementary Therapies in Medicine, October 2019
—
The prior medical literature offers little guidance as to how pain relief and side effect manifestation may vary across commonly used and commercially available cannabis product types. We used the largest dataset in the United States of real-time responses to and side effect r…
SCC member Kevin M. Takakuwa, MD outlines on the historical impact of cannabis and its relevance to pediatric practice. The article highlights how cannabis may benefit seizure disorders in children and young adults.
Pain Medicine, 16 September 2019
—
This editorial is occasioned by the publication in Pain Medicine of two quite distinct articles [1,2] on the topical subject of cannabis and pain. As a point of departure, it is necessary to define terms. Cannabis sativa L. is a highly variable biochemical and morphological pl…
Cannabis and Cannabinoid Research, 4 September 2019
—
Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabi…
Psychiatria Danubina, September 2019
—
BACKGROUND: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by cyclic vomiting and compulsive need to take hot showers in the context of chronic cannabis use. Physicians’ lack of knowledge of CHS often results in a diagnostic delay of several years. The purpose of this…
JAMA, 9 August 2019
—
Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…
Journal of Palliative Medicine, 6 August 2019
—
Objectives: To determine the relative contributions of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients’ self-ratings of efficacy for common palliative care symptoms. Design: This is an electronic record-based retrospective cohort study. Model development used logi…
Therapeutic Advances in Medical Oncology, 1 August 2019
—
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symp…
Medicine, August 2019
—
Ulcerative colitis (UC) is a chronic inflammatory process that is occasionally associated with complications that cause significant morbidity and mortality. Studies in experimental animal models have demonstrated a beneficial effect of cannabis on intestinal inflammation. It i…